Login to get immediate access to this content.
LoginSpeaker: Yelena Y. Janjigian, USA
Abstract discussed:
- 1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03): Watch the presentation from ESMO 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published October 2024